SDP 01873
Alternative Names: SDP-01873Latest Information Update: 22 Jan 2026
At a glance
- Originator Jiangsu Hengrui Medicine Co.; Shanghai Shengdi Pharmaceutical
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action ERBB-3 receptor antagonists; Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Non-small cell lung cancer
Most Recent Events
- 25 Apr 2025 Preclinical trials in Cancer in China (unspecified route)
- 25 Apr 2025 Preclinical trials in Colorectal cancer in China (Parenteral)
- 25 Apr 2025 Pharmacodynamics and adverse events data from preclinical studies in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)